Genetic Immunization Elicits Antigen-Specific Protective Immune Responses and Decreases Disease Severity inTrypanosoma cruziInfection
Open Access
- 1 October 2002
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 70 (10) , 5547-5555
- https://doi.org/10.1128/iai.70.10.5547-5555.2002
Abstract
Immunity to Trypanosoma cruzi requires elicitation of humoral and cell-mediated immune responses to extracellular trypomastigotes and intracellular amastigotes. In this study, the effectiveness of the T. cruzi trans-sialidase family (ts) genes ASP-1, ASP-2, and TSA-1 as genetic vaccines was assessed. Immunization of mice with plasmids encoding ASP-1, ASP-2, or TSA-1 elicited poor antigen-specific cytotoxic-T-lymphocyte (CTL) activity and T. cruzi-specific antibody responses. Codelivery of interleukin-12 and granulocyte-macrophage colony-stimulating factor plasmids with antigen-encoding plasmids resulted in a substantial increase in CTL activity and antibody production and in increased resistance to T. cruzi infection. In pooled results from two to four experiments, 30 to 60% of mice immunized with antigen-encoding plasmids and 60 to 80% of mice immunized with antigen-encoding plasmids plus cytokine adjuvants survived a lethal challenge with T. cruzi. In comparison, 90% of control mice injected with empty plasmid DNA died during the acute phase of infection. However, the pool of three ts genes provided no greater protection than the most effective single gene (ASP-2) either with or without coadministration of cytokine plasmids. Importantly, the extent of tissue parasitism, inflammation, and associated tissue damage in skeletal muscles during the chronic phase of T. cruzi infection in mice immunized with antigen-encoding plasmids plus cytokine adjuvants was remarkably reduced compared to mice immunized with only cytokine adjuvants or empty plasmid DNA. These results identify new vaccine candidates and establish some of the methodologies that might be needed to develop effective vaccine-mediated control of T. cruzi infection. In addition, this work provides the first evidence that prophylactic genetic immunization can prevent the development of Chagas’ disease.Keywords
This publication has 58 references indexed in Scilit:
- DNA Immunization withTrypanosoma cruziHSP70 Fused to the KMP11 Protein Elicits a Cytotoxic and Humoral Immune Response against the Antigen and Leads to ProtectionInfection and Immunity, 2001
- The immunization of A2/Kb transgenic mice with the KMP11-HSP70 fusion protein induces CTL response against human cells expressing the T. cruzi KMP11 antigen: identification of A2-restricted epitopesMolecular Immunology, 2001
- Augmentation of Immune Responses to Hepatitis E Virus ORF2 DNA Vaccination by Codelivery of Cytokine GenesViral Immunology, 2000
- Chagas Disease Etiology: Autoimmunity or Parasite Persistence?Parasitology Today, 1999
- Cytokine Molecular Adjuvants Modulate Immune Responses Induced by DNA Vaccine Constructs for HIV-1 and SIVJournal of Interferon & Cytokine Research, 1999
- Genetic Immunization with Glycoprotein 63 cDNA Results in a Helper T Cell Type 1 Immune Response and Protection in a Murine Model of LeishmaniasisHuman Gene Therapy, 1998
- DNA vaccinesLife Sciences, 1996
- Exact prediction of a natural T cell epitopeEuropean Journal of Immunology, 1991
- Nucleotide sequence and transcription of a trypomastigote surface antigen gene of Trypanosoma cruziMolecular and Biochemical Parasitology, 1991